Evaluation of bleeding in patients receiving direct oral anticoagulants

Erika L. Hellenbart, Kathleen D. Faulkenberg, Shannon Finks

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.

Original languageEnglish (US)
Pages (from-to)325-342
Number of pages18
JournalVascular health and risk management
Volume13
DOIs
StatePublished - Aug 23 2017

Fingerprint

Anticoagulants
Hemorrhage
Vitamin K
Intracranial Hemorrhages
Venous Thromboembolism
Embolism
Drug-Related Side Effects and Adverse Reactions
Atrial Fibrillation
Randomized Controlled Trials
Stroke
Guidelines
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Evaluation of bleeding in patients receiving direct oral anticoagulants. / Hellenbart, Erika L.; Faulkenberg, Kathleen D.; Finks, Shannon.

In: Vascular health and risk management, Vol. 13, 23.08.2017, p. 325-342.

Research output: Contribution to journalArticle

Hellenbart, Erika L. ; Faulkenberg, Kathleen D. ; Finks, Shannon. / Evaluation of bleeding in patients receiving direct oral anticoagulants. In: Vascular health and risk management. 2017 ; Vol. 13. pp. 325-342.
@article{ac2dd83391f74081b5f5137995f923b5,
title = "Evaluation of bleeding in patients receiving direct oral anticoagulants",
abstract = "Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.",
author = "Hellenbart, {Erika L.} and Faulkenberg, {Kathleen D.} and Shannon Finks",
year = "2017",
month = "8",
day = "23",
doi = "10.2147/VHRM.S121661",
language = "English (US)",
volume = "13",
pages = "325--342",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Evaluation of bleeding in patients receiving direct oral anticoagulants

AU - Hellenbart, Erika L.

AU - Faulkenberg, Kathleen D.

AU - Finks, Shannon

PY - 2017/8/23

Y1 - 2017/8/23

N2 - Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.

AB - Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.

UR - http://www.scopus.com/inward/record.url?scp=85029168976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029168976&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S121661

DO - 10.2147/VHRM.S121661

M3 - Article

VL - 13

SP - 325

EP - 342

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -